Oakmark's AstraZeneca Bet: How the World's Top Drugmaker is Creating a Growth Opportunity
Oakmark Global Fund, AstraZeneca (AZN) hissesini yeni pozisyon olarak ekleyerek, dünyanın en büyük biyofarmasötik firmalarından birine uzun vadeli yat
Oakmark Global Fund has added AstraZeneca (AZN) as a new position, betting on one of the world's largest biopharmaceutical companies. With a market cap of $261.12 billion, the company is seen as a high-growth opportunity due to its robust on-market portfolio and sector-leading late-stage pipeline. CEO Pascal Soriot is considered one of the industry's top executives. While AZN has gained 18.55% over the past 52 weeks, it posted a -3.75% decline in the last month. Oakmark views the addition as a value opportunity, citing concerns over U.S. regulations. Could this move represent a strategic play in the face of broader negativity in the biopharmaceutical sector?
Related News & Analysis
View All →
South West Water's Sewage Scandal and Bill Surge: A Dark Side of the Water Sector
Iran Sanctions: Operation Economic Outcast Auctions Dollar Access
A Phoenix Firm’s Quick Demise: From £3 Million Debt to Liquidation in Three Months
Bessent’s ‘D-Day’ Iran Sanctions Threat: Dubai Banks Stay Open, Flights Persist
UK Devolution: Cities Surge While Rural Areas Lag
Half a Year into the Iran War, Global Economy Pulls Off a 'Mission Impossible' Act, Trump Family Among the Winners
Latest Market News
All News →
August 30, 2026 Fuel Prices: Current Gasoline and Diesel Rates in Istanbul, Ankara and Izmir
BİM's Shock Discounts: Grocery and Detergent Prices Hit Record Lows
Galatasaray Secures Rafael Leao: €38M Transfer Fee and €10M Salary
South West Water's Sewage Scandal and Bill Surge: A Dark Side of the Water Sector
G20 Issues Stern Warning to China: **$1.2 Trillion** Trade Surplus Unsustainable
